O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor-induced resistance against temozolomide in human melanoma cells

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2807-2815

  Fontijn, Dennis ^a   Adema, Auke D ^a   Bhakat, Kishor K ^b   Pinedo, Herbert M ^a   Peters, Godefridus J ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; 6 O BENZYLGUANINE; AZACITIDINE; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; DOCETAXEL; DOXORUBICIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN MSH2; MISMATCH REPAIR PROTEIN MSH6; PROTEIN MLH1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; GUANINE; LUCIFERASE; MESSENGER RNA; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RNA;

ADVANCED CANCER; ARTICLE; CANCER RESISTANCE; CLONE; CONTROLLED STUDY; DNA METHYLATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE VECTOR; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; BASE MISPAIRING; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MISMATCH REPAIR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; BLOTTING, WESTERN; DACARBAZINE; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FIBROBLAST GROWTH FACTOR 2; GUANINE; HUMANS; LUCIFERASES; MELANOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 35848946607     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0044     Document Type: Article

References (46)

1. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
2. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7.
3. Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8.
4. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
5. Margison GP, Santibáñez-Koref MF. O6-Alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002;24:255-66.
6. Dempke W, Nehls P, Wandl U, Soll D, Schmidt CG, Osieka R. Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. J Cancer Res Clin Oncol 1987;113:387-91.
7. Pepponi R, Marra G, Fuggetta MP, et al. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003;304:661-8.
8. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
10. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988;3:177-86.
11. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989;8:3685-91.
12. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 1992;7:2303-13.
13. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997;3:887-93.
14. Shaulian E, Resnitzky D, Shifman O, et al. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997;15:2717-25.
15. Wieder R, Wang H, Shirke S, et al. Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells. Growth Factors 1997;15:41-60.
16. Dini G, Funghini S, Witort E, et al. Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential. J Cell Physiol 2002;193:64-72.
17. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121-6.
18. Florkiewicz RZ, Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A 1989;86:3978-81.
19. Van Muijen GN, Cornelissen LM, Jansen CF, et al. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 1991;9:259-72.
20. Lockshin A, Giovanella BC, De Ipolyi PD, et al. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res 1985;45:345-50.
21. Fontijn D, Duyndam MCA, Beliën JAM, Gallegoz Ruiz MI, Pinedo HM, Boven E. The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis. Melanoma Res 2007;17:155-68.
22. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;7:248-54.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
24. Bhakat KK, Mitra S. Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem 2000;275:34197-204.
25. Biswas T, Ramana CV, Srinivasan G, et al. Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 1999;18:525-32.
26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
27. Fishel ML, Delaney SM, Friesen LD, et al. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther 2003;2:633-40.
28. Lee SM, Rafferty JA, Elder RH, et al. Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. Br J Cancer 1992;66:355-60.
29. Moriwaki S, Nishigori C, Takebe H, Imamura S. O6-alkylguanine-DNA alkyltransferase activity in human malignant melanoma. J Dermatol Sci 1992;4:6-10.
30. Redmond SM, Joncourt F, Buser K, et al. Assessment of Pglycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991;51:2092-7.
31. Zaidi NH, Liu L, Gerson SL. Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. Clin Cancer Res 1996;2:577-84.
32. Kokkinakis DM, Ahmed MM, Delgado R, Fruitwala MM, Mohiuddin M, Albores-Saavedra J. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 1997;57:5360-8.
33. Citron M, Schoenhaus M, Graver M, et al. O6-methylguanine-DNA methyltransferase in human normal and malignant lung tissues. Cancer Invest 1993;11:258-63.
34. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-14.
35. Chen ZP, Yarosh D, Garcia Y, et al. Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999;26:104-9.
36. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
37. Lage H, Christmann M, Kern MA, et al. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999;80:744-50.
38. Dell'Era P, Coco L, Ronca R, Sennino B, Presta M. Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. Oncogene 2002;21:2433-40.
39. Harris LC, Potter PM, Tano K, Shiota S, Mitra S, Brent TP. Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res 1991;19:6163-7.
40. Lind GE, Thorstensen L, Løvig T, et al. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 2004;3:28.
41. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-33.
42. Myohanen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 1998;58:591-3.
43. Bhakat KK, Mitra S. CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 2003;24:1337-45.
44. Boldogh I, Ramana CV, Chen Z, et al. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res 1998;58:3950-6.
45. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997;40:266-72.
46. Ueno T, Hee Ko S, Grubbs E, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006;5:732-8.